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Abstract: Aldosterone regulates blood pressure through its effects on the cardiovascular system and 
kidney.  Aldosterone can also contribute to the development of hypertension that leading to chronic 
pathologies such as nephropathy and renal fibrosis. Aldosterone directly modulates renal cell 
proliferation and differentiation as part of normal kidney development. The stimulation of rapidly 
activated protein kinase cascades is one facet of how aldosterone regulates renal cell growth. These 
cascades may also contribute to myofibroblastic transformation and cell proliferation observed in 
pathological conditions of the kidney. Polycystic kidney disease is a genetic disorder that is accelerated 
by hypertension. EGFR-dependent proliferation of the renal epithelium is a factor in cyst development 
and trans-activation of EGFR is a key feature in initiating aldosterone-induced signalling cascades. 
Delineating the components of aldosterone-induced signalling cascades may identify novel therapeutic 
targets for proliferative diseases of the kidney. 
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Abstract 
Aldosterone regulates blood pressure through its effects on the cardiovascular system 
and kidney.  Aldosterone can also contribute to the development of hypertension that 
leading to chronic pathologies such as nephropathy and renal fibrosis. Aldosterone 
directly modulates renal cell proliferation and differentiation as part of normal kidney 
development. The stimulation of rapidly activated protein kinase cascades is one facet 
of how aldosterone regulates renal cell growth. These cascades may also contribute to 
myofibroblastic transformation and cell proliferation observed in pathological 
conditions of the kidney. Polycystic kidney disease is a genetic disorder that is 
accelerated by hypertension. EGFR-dependent proliferation of the renal epithelium is a 
factor in cyst development and trans-activation of EGFR is a key feature in initiating 
aldosterone-induced signalling cascades. Delineating the components of aldosterone-
induced signalling cascades may identify novel therapeutic targets for proliferative 
diseases of the kidney. 
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Introduction 
The rennin-angiotensin-aldosterone system (RAAS) is a key regulator of systemic blood 
pressure through its direct action on the renal and cardiovascular systems [1, 2]. The 
release of aldosterone by the adrenal glands contributes to the homeostatic regulation of 
blood pressure under normal physiological conditions via a number of interlinked 
mechanisms including the modulation of vascular tone and the rate of electrolyte 
transport across target epithelia such as the distal nephron. Defective RAAS activity is a 
contributory factor in congenital and acquired hypertension [3]; consequently the 
individual receptors, enzymes and effectors of the RAAS cascade are important 
therapeutic targets in the treatment of this condition. The kidney is a key target organ 
for aldosterone action and the regulation of the rate of Na
+
 absorption by the distal 
nephron is an important factor influencing systemic blood pressure. The biological 
effects of aldosterone are initiated through the binding of the hormone to the 
mineralocorticoid receptor (MR), which is expressed by all aldosterone responsive 
tissues including the distal nephron [4] and the rennin secreting mesangial cells of the 
juxtaglomerular apparatus [5]. In the distal nephron, the aldosterone-induced 
modulation of ion transporter activity is mediated through the transcriptional effects of 
MR on transporter subunit and regulatory protein expression or through the 
phosphorylation of transporters and regulatory molecules by rapidly activated protein 
kinases. The combined transcriptional and signalling effects of aldosterone on the renal 
epithelium leads to the modulation of ion fluxes that impact upon whole body 
electrolyte homeostasis. The regulation of Na
+
 and K
+
 transport are held to be the most 
important functions for aldosterone in the kidney. However, recent evidence points to 
aldosterone having a more complex role in supporting renal cell differentiation and also 
in contributing to pathological processes in the kidney. The direct effects of aldosterone 
on renal pathology through its effects on MR-expressing cells in the renal tubule are 
adjunct to the histological damage inflicted on renal tissue by systemic hypertension. 
 
Aldosterone modulates the growth of renal cells both in culture and in vivo. Evidence 
points to a contribution from aldosterone to normal renal tubule cell proliferation and 
differentiation from isolated renal stem cells [6] and also from studies in vivo using 
juvenile animal models [7]. Aldosterone may also contribute to the development of 
pathological conditions in the kidney through dysregulation of renal cell growth in the 
adult resulting in fibrosis or epithelial hyperplasia. The growth stimulatory effects of 
aldosterone, either hypertrophy or hyperplasia depending on the cell type investigated; 
result from the synergism between the transcriptional and rapid signalling responses 
stimulated by the hormone. The cross-talk between these two facets of aldosterone 
action is a prominent aspect of current research and blurs the distinction between 
genomic and non-genomic effects of steroids. Essentially aldosterone not only promotes 
the activation of protein kinase signalling cascades which contribute to cell growth but 
also up-regulates the expression of key signalling intermediates to amplify the 
sensitivity and magnitude of responses to aldosterone itself and other growth factors. 
The mechanisms by which aldosterone modulates the growth of renal cells will be the 
subject of this review, in particular the roles of the rapidly activated signalling cascades 
in potentiating and sustaining the transcriptional response to aldosterone in proliferating 
renal cells. 
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Aldosterone and Renal Stem Cell Differentiation 
The development of each renal tubule from progenitor cells is a complex process reliant 
upon the co-operative actions of nephrogenic mesenchymal stem cells which give rise to 
the proximal tubule, loop of Henle and distal tubule, and other stem cells located in the 
collecting duct ampullae that form the collecting duct tubule itself. Cell proliferation 
following stem cell stimulation leading to the formation of S-shaped tubule bodies 
marks the earliest stage of nephron development in the mesenchymal parenchyma. The 
signalling processes which co-ordinate the two groups of stem cells to form a single 
nephron are poorly understood. Isolated renal stem cells from neonatal animals can be 
cultured using an in vitro serum-free perfusion system with the embryonic cells seeded 
between two layers of porous polyester matrix [8]. However, various combinations of 
typically used cell culture supplements such as epidermal growth factor (EGF), insulin, 
transferrin, selenium, retinoic acid, bovine pituitary extract or cholecalciferol do not 
stimulate tubule formation in this model [6]. Under these culture conditions the 
progenitor cells will develop hollow, tubular structures only in the presence of 100 nM 
aldosterone. These tubular structures display at least partial differentiation with the 
expression of N-acetylgalactosamine on surface glycoproteins as a marker for the 
collecting duct and also some degree of apical to basolateral epithelial polarity indicated 
by tight junction formation. The aldosterone biochemical precursors: cholesterol and 
pregnenolone did not mimic this effect on renal stem cells while progesterone and 11-
deoxycorticosterone treatment resulted in only partial tubule development. The MR 
antagonist spironolactone inhibited the aldosterone-induced tubule formation while the 
GR agonist dexamethasone stimulated disorganized cell proliferation but no tubule 
formation [9]. Aldosterone thus acts as a potent differentiation factor for renal stem cells 
in neonatal animals. However, similar tubulogenic effects have not been observed in 
cells isolated from adult animals and the molecular basis of aldosterone-induced tubule 
differentiation has not been established to date. 
 
Aldosterone-induced Signalling and Renal Cell Growth 
The field of aldosterone-induced rapid signalling has developed greatly in recent years 
with the identification of the physiological roles of these signalling cascades in the cell 
and in the whole organism. The regulation of ion fluxes has always been seen as the key 
function of aldosterone in the kidney [10] and consequently attention has been focused 
on coupling aldosterone-induced signalling cascades to Na
+
 and K
+
 transport. It has also 
been known for some time that aldosterone can modulate the proliferation of MR 
expressing cells in vitro [11]. Modulation of cell growth by aldosterone; whether it is a 
metabolic stimulation (hypertrophy) or the stimulation of cell proliferation (hyperplasia) 
requires co-ordination of rapid signalling and transcriptional changes. The activation of 
several signalling cascades by aldosterone has been identified in cells derived from the 
distal nephron including the PKC  [12], PKD1 [13] and ERK1/2 mitogen activated 
protein (MAP) kinase [14] cascades. A number of the signalling cascades rapidly 
activated by aldosterone such as the Ca
2+
-dependent PKC isoforms and ERK1/2 also 
promote cell proliferation in response to mitogenic agonists. This begs the question of 
whether aldosterone modulates renal cell growth through the activation of these 
cascades.  
 
Aldosterone treatment of isolated renal cortical collecting duct cells stimulates the 
biphasic activation of the ERK1/2 cascade with an early phase of transient activation 
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 5 
followed by a more sustained period of activation. Recent work has investigated the role 
of aldosterone on ERK1/2 signalling in vivo. Dosing new born rats with the MR 
antagonist spironolactone for 7 days resulted in an increase in apoptosis detected in 
kidney sections [15]. This observation suggests that at least in juvenile animals, 
aldosterone plays a role in inhibiting apoptosis.  Spironolactone-induced apoptosis was 
most prominent in the tubule cells of the renal cortex where MR is highly expressed. 
MR antagonism resulted in a significant reduction in ERK1/2 and p38 MAP kinase 
protein expression but a slight increase in the abundance of the mRNA of these two 
kinases. Conversely JNK-2 expression was induced by spironolactone in the cells of the 
glomeruli and in the cortical tubules [15]. A role for aldosterone in regulating apoptosis 
in the adult kidney has also been described. Aldosterone stimulated both apoptotic and 
mitogenic effects in human mesangial cells, which correlated with de-phosphorylation 
of the Bcl-2 family protein Bad and the release of cytochrome c into the cytoplasm. In 
vivo, aldosterone had a similar pro-apoptotic effect on rat mesangial cells which was 
eplerenone-sensitive and correlated with an increase in systolic blood pressure and 
albuminuria [16]. Aldosterone stimulated ERK1/2 activation within 10 min of treatment 
in mesangial cells which was also eplerenone-sensitive and led to ERK1/2-dependent 
cell proliferation [5]. Aldosterone is therefore involved in regulating the delicate 
balance between proliferation and apoptosis in mature and immature renal tissues.  
 
The sustained activation of the ERK1/2 signalling cascade promotes growth factor-
stimulated cell cycle progression in fibroblasts. Transient activation of ERK1/2 is 
insufficient to commit stimulated cells to complete cell division [17]. The protein kinase 
D (PKD) family of serine threonine protein kinases are involved in modulating critical 
cellular processes including sub-cellular trafficking, hypertrophy, apoptosis and 
proliferation and are activated in response to diverse agonists [18]. The expression and 
activation of PKD family proteins is pre-requisite for sustained activation of ERK1/2 in 
response to non-steroid growth factors that act through G-protein coupled receptors [17, 
19]. PKD family isoforms are in some way responsible for stabilizing the initial growth 
factor-stimulated ERK1/2 activation [20]. The MR-dependent autophosphorylation of 
protein kinase D occurs within 5 min of treating CCD cells with aldosterone [13]. The 
rapid PKD activation coincides temporally with initial ERK1/2 activation in these cells. 
The activation of both PKD and ERK1/2 by aldosterone are dependent on the trans-
activation and phosphorylation of the EGF receptor (EGFR) by c-Src tyrosine kinase 
[13, 21, 22]. In wild-type CCD cells aldosterone stimulates ERK1/2 activation which 
remains detectable 2 hours after treatment. In CCD cells suppressed in PKD1 
expression, aldosterone stimulates only a transient activation of ERK1/2 (McEneaney et 
al. in press). Aldosterone promotes the growth of sub-confluent CCD cells but not of the 
PKD1 suppressed cells (Fig. 1), consequently the behaviour of aldosterone as a renal 
growth factor is at least partially dependent on PKD1 activation.  
 
Aldosterone-induced Signalling and Nephropathy 
Abnormal cell growth is a factor in the progression of pathogenic renal conditions such 
as chronic kidney disease, polycystic kidney disease and diabetes associated 
nephropathy. The growth promoting effects of aldosterone on renal tubule cells has 
been proposed as a factor contributing to the rate of progression of these conditions. 
However, the pathological effects of circulating aldosterone can only be one component 
of a multi-factorial process which displays chronic progression leading to renal damage. 
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 6 
Progressive tissue deterioration results from cell growth dysregulation and extracellular 
matrix deposition leading to fibrosis and inflammation. Animal experiments and human 
clinical trials have demonstrated an additive effect of aldosterone antagonism with 
RAAS blockade in attenuating renal damage. MR antagonism in combination with 
angiotensin-converting enzyme (ACE) inhibitors attenuates the progression of diabetic 
and non-diabetic nephropathies [23]. A diabetic rat model revealed that the MR 
antagonist eplerenone in combination with the ACE inhibitor, enalapril enhanced 
glomerular filtration and suppressed glomerulosclerosis with a concurrent reduction in 
TGF- 1, Collagen type-IV and plasminogen activator factor-1 expression [24]. 
Aldosterone also stimulates NADPH oxidase-dependent production of reactive oxygen 
species in renal cells that accelerates fibrosis that can be attenuated using eplerenone 
[25] . The NF B transcriptional pathway is also activated in response to aldosterone in 
renal principal collecting duct cells however this was mediated by SGK activity rather 
than the stimulation of MAP kinases. The transcription of pro-inflammatory cytokine 
genes such as IL-1  and IL-6 are up-regulated by NF B [26]. The activation of NF B-
dependent transcription in this experimental system was MR-dependent and was 
antagonized by concurrent activation of the glucocorticoid receptor. Aldosterone 
treatment of mesangial cells results in a rapid phosphorylation of myosin phosphatase 
target subunit-1, a substrate for Rho kinase within 20 min of hormone treatment and 
also results in an increase in actin polymerization [27]. The state of hypertrophy 
stimulated by aldosterone in these cells correlates with the subsequent up-regulation in 
the expression of collagen types I, III and IV and of -smooth muscle actin, a marker 
for myofibroblastic transformation. These changes, stimulated by aldosterone could be 
blocked by eplerenone and the Rho kinase inhibitor Y27632 demonstrating that this 
cascade plays a critical role in the differentiation effects of aldosterone. 
 
Aldosterone, EGFR and Polycystic kidney disease 
The aberrant stimulation of cell proliferation in the epithelium of the distal nephron is 
one factor in the development of polycystic kidney disease [28]. Susceptible individuals 
have a genetic predisposition to developing autosomal recessive polycystic kidney 
disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) 
through mutations in the genes encoding the fibrocystin or polycystin 1 and 2 genes 
respectively [29, 30]. The products of these genes are multi-functional structural 
membrane proteins that have roles in cell polarization, tight junction integrity, ion 
transport and signal transduction. Chronic hypertension is an exacerbating factor in the 
progression of polycystic kidney disease [31] and controlling hypertension through the 
administration of MR antagonists is one approach to therapeutic intervention [32]. 
Renal cyst formation and enlargement is a consequence of epithelial proliferation [33] 
and ion transport dysregulation. The formation of cysts in ARPKD is mainly localized 
to the MR-expressing epithelium of the distal nephron [33] and this points to a role for 
aldosterone in promoting aberrant proliferation in the distal nephron. Silencing of the 
ARPKD-associated fibrocystin gene in HEK293 cells produced a hyper-proliferative 
response to EGF and resulted in over-activation of the ERK1/2 cascade following EGF 
treatment [34]. Over-expression of Heparin-binding EGF is detected in ARPKD and 
EGF antagonistic antibodies suppress the mitogenic activity of cleared cystic fluid [35].  
The abundance of EGFR in cells from the renal tubule is responsive to aldosterone-
dependent transcription [36] and expression of EGFR is necessary to permit the 
stimulation of rapid signalling responses by aldosterone in CHO cells [37]. The 
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 7 
activation of ERK1/2 signalling by aldosterone in cells derived from the distal nephron 
has been described by several groups including our own [38, 39] and this response has 
been linked to trans-activation of EGFR [40]. The nuclear localization of ERK1/2 
occurs subsequent to its activation and is consistent with its role as a regulator of 
transcription factors. The nuclear translocation of ERK1/2 in response to the 
aldosterone treatment of CCD cells was blocked by EGFR inhibition (Fig. 2). 
Antagonism of the RAAS to control hypertension as a means of slowing cyst formation 
in ADPKD is the subject of an on-going clinical investigation [41].  
 
Conclusion 
Aldosterone is emerging as an important factor in regulating the growth and 
differentiation of renal cells both in vivo and in vitro. Aldosterone has an indirect effect 
on the pathology of renal diseases such as renal fibrosis and polycystic kidney disease 
through the detrimental effects of systemic hypertension. Aldosterone also has direct 
effects on renal pathology through the rapid activation of protein kinase signalling 
cascades in cells of the renal epithelium to stimulate cell proliferation and hypertrophy 
(Fig. 3). Pharmacological intervention in the activation of these aldosterone-induced 
signalling cascades, particularly those coupled to EGFR trans-activation may provide 
novel avenues for the treatment of chronic kidney diseases in combination with existing 
therapies. 
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Figure Legends 
Figure 1 
Suppression of PKD1 expression inhibits aldosterone induced CCD cell 
proliferation. M1-CCD cells and cells stably suppressed in PKD1 expression using a 
plasmid expressing a PKD1 specific siRNA were seeded at a density of 1 x 10
4
 cells per 
microtitre plate well, in DMEM/F12 containing 5μM dexamethasone and 10% FBS. 
The cells were left to adhere overnight at 37°C in a humidified atmosphere of 5% CO2. 
The medium was then exchanged for serum-free DMEM/F12, containing 1μM 
dexamethasone for 24h. Cells were treated with 10nM aldosterone or vehicle control for 
72h. Following treatment, the medium was carefully removed. The cells were detached 
using trypsin and re-suspended in a final volume of 100 μl fresh medium. Cells were 
counted using a Neubauer chamber, 4 wells per treatment for each cell line. Aldosterone 
stimulated a two-fold increase in cell number above basal proliferation rates that was 
blocked by suppression of PKD1 expression.  
 
Figure 2 
ERK1/2 nuclear localization following aldosterone treatment is EGFR-dependent. 
Murine M1-CCD cells were maintained in serum free medium for 24 h then treated with 
aldosterone (10 nM) for 2 min. The sub-cellular distribution of ERK1/2 MAP kinase 
was determined by immuno-fluorescence using an ERK1/2-specific antibody and 
detected using an anti-rabbit secondary antibody conjugated to Alexa488. ERK1/2 
became localized to the nucleus following aldosterone treatment. The nuclear 
localization of ERK1/2 in response to aldosterone was blocked by pre-incubation with 
the EGFR-specific inhibitor tyrphostin AG1478 (1 M). The nuclear localization of 
ERK1/2 following aldosterone treatment is dependent on trans-activation of EGFR. 
 
Figure 3 
Aldosterone and growth dysregulation in renal cortical collecting duct cells. 
Chronic renal injury occurs as a result of multiple synergistic processes. Aldosterone 
action can be one of these processes. The interaction between aldosterone and the 
mineralocorticoid receptor (MR) promotes the nuclear localization of MR where it 
interacts with other transcription factors (TFs) to modulate gene expression. Signalling 
events coupled to MR include the Src-dependent trans-activation of EGFR leading to 
activation of the ERK1/2 and PKD1 signalling cascades. PKD1 activation stabilizes the 
activation of ERK1/2, while ERK1/2 phosphorylates MR and other transcription factors 
to modulate their activity and contribute to cell growth responses including 
proliferation. Serum and glucocorticoid regulated kinase-1 (SGK) is one of the earliest 
detected proteins to be up-regulated by aldosterone. SGK activation promotes NF B-
dependent transcription leading to the release of pro-inflammatory cytokines IL-1  and 
IL-6 to promote renal fibrosis. 
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